Sun Pharmaceutical Industries Limited
SUNPHARMA
Pozycja w akcjach
#522
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Cena akcji
$19.24
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$46.15B
Zmiana (1 dzień)
-0.97%
Zmiana (1 rok)
0.11%
Kraj
IN
Handel Sun Pharmaceutical Industries Limited (SUNPHARMA)
Kategoria
Healthcare
Zyski dla Sun Pharmaceutical Industries Limited (SUNPHARMA)
Zyski w Jun 2026 TTM: $1.76B
Według najnowszych raportów finansowych Sun Pharmaceutical Industries Limited, obecny zysk firmy wynosi $1.76B. W roku 2024 firma osiągnęła zysk w wysokości $1.33B, wzrost w porównaniu do zysku z roku 2023, który wynosił $1.14B. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Sun Pharmaceutical Industries Limited od 2004 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $1.76B | 9.86% |
| 2025 | $1.61B | 21.21% |
| 2024 | $1.33B | 16.34% |
| 2023 | $1.14B | 93.65% |
| 2022 | $588.17M | 54.49% |
| 2021 | $380.72M | -42.58% |
| 2020 | $663.01M | 20.88% |
| 2019 | $548.49M | 3.41% |
| 2018 | $530.42M | -62.03% |
| 2017 | $1.40B | 40.80% |
| 2016 | $992.01M | -3.13% |
| 2015 | $1.02B | 33.99% |
| 2014 | $764.30M | -3.90% |
| 2013 | $795.33M | 20.15% |
| 2012 | $661.93M | 44.90% |
| 2011 | $456.82M | 45.01% |
| 2010 | $315.02M | -17.95% |
| 2009 | $383.94M | -3.94% |
| 2008 | $399.69M | 107.87% |
| 2007 | $192.27M | 43.47% |
| 2006 | $134.02M | 39.03% |
| 2005 | $96.39M | 9.76% |
| 2004 | $87.82M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
